AIDS Current Events | AIDS News | 5
|
| Page
5 of
17 |
335 Results |
|
|
|
Sort By:
Page Views | Date |
Why were the HIV prevention trials in commercial sex workers abandoned?
One promising approach to help stem the global HIV epidemic is to give commercial sex workers an HIV medication (such as the drug tenofovir) before they have high risk sex in the hope of reducing their chances of becoming infected, an approach called "pre-exposure prophylaxis" (PREP). view more (2005-07-19)
Pitt researchers find candidates for new HIV drugs
While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease. view more (2009-10-14)
Global HIV Vaccine Enterprise Announces Strategic Plan
A Much-Needed Shot in the Arm for HIV Vaccine Development International efforts towards developing a vaccine against HIV infection have been given a much-needed boost by the publication today of the Global HIV/AIDS Vaccine Enterprise's scientific strategic plan, published online in the freely available, open-access global health journal PLoS... view more... (2005-01-10)
AIDS inflicts specific pattern of brain damage, reveals UCLA/Pittsburgh imaging study
A new UCLA/University of Pittsburgh imaging study for the first time shows the selective pattern of destruction inflicted by AIDS on brain regions that control motor, language and sensory functions. view more (2005-10-11)
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease. view more (2008-09-17)
How HIV cripples immune cells
In order to be able to ward off disease pathogens, immune cells must be mobile and be able to establish contact with each other. The working group around Professor Dr. Oliver Fackler in the Virology Department of the Hygiene Institute of the Heidelberg University Hospital has discovered a mechanism in an animal model revealing how HIV, the AIDS... view more... (2009-09-17)
New Approaches To HIV Treatment In Less-developed Countries (pp 404, 410)
Two Viewpoint articles in this week's issue of THE LANCET highlight how the use of highly-active antiretroviral therapy (HAART) for HIV-1 treatment - currently only widely available in industrialised countries - could become accessible in less-developed settings. Both articles suggest new strategies for implementing HAART using infrastructure... view more... (2001-08-01)
Expansion of monocyte subset could serve as a biomarker for HIV progressions
An increase in the CD163+/CD16+ monocyte subset could be a biomarker for the progression of HIV disease, according to researchers at Temple University. view more (2008-03-28)
Six months after start of treatment could be optimum time for making prognosis in patients with HIV/AIDS (p 679)
Issue 30 August 2003 Embargoed 0001 h (London time) 29 August 2003. An international study in this week's issue of THE LANCET suggests that prognosis for patients with HIV/AIDS might be more reliably determined six months after initiation of highly active antiretroviral therapy (HAART), rather than before the start of treatment. HAART became... view more... (2003-08-27)
No-entry zones for AIDS virus
The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs. view more (2009-11-13)
Reduction In HIV-1 Incidence Among Rural Ugandans Gives Hope To Other African Countries (pp 3, 41, 78)
A study in this week's issue of THE LANCET highlights a reduction in both HIV-1 incidence (the number of new cases) and prevalence (the number of cases in the population) from the beginning to the end of the past decade among a rural Ugandan population. Authors of the study conclude that the results could offer hope for other sub-Saharan countries... view more... (2002-07-03)
Highly active antiretroviral therapy of similar benefit for HIV-infected injection drug users
Contrary to the belief that HIV-infected injection drug users (IDUs) receive less benefit from highly active antiretroviral therapy (HAART), new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART. view more (2008-08-04)
IAVI statement on new analysis of STEP large-scale AIDS vaccine trial
The International AIDS Vaccine Initiative (IAVI) issued the following statement from its President and CEO, Dr. Seth Berkley, following the release of the first analysis of the entire study population from a late-stage AIDS vaccine trial, known as the STEP study. view more (2007-11-08)
Causes of global death and disease in the next 25 years
In 1993, the World Bank sponsored the 1990 Global Burden of Disease study carried out by researchers at Harvard University and the World Health Organization (WHO). This study provided the first comprehensive global estimates of death and illness by age, sex, and region. view more (2006-11-28)
New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health
Three new studies published in the June 2008 edition of Otolaryngology - Head and Neck Surgery focus on what role gender plays in the prognosis of oral tongue cancer, chronic ear infections in children, and the success rates of hearing aid implants in the elderly. view more (2008-06-02)
"EuroVacc 02" HIV Vaccine trial begins
The European Vaccine Effort against HIV/AIDS, today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan... view more... (2005-02-16)
Health as a mathematical model
Strategic management in AIDS prevention and hospital funding Vienna (FWF) - Having developed into a severe financial problem in many countries, AIDS has long ceased to be a purely emotional issue. Financial resources are channelled into preventive measures and into the treatment of AIDS patients with the aim of achieving maximum efficiency at... view more... (2001-08-21)
Study finds strong demand for HIV meds after high-risk sex
People who do not have HIV but seek antiretroviral medications following high-risk sexual encounters are very likely to complete the full monthlong drug regimen, according to a new UCLA AIDS Institute study. Moreover, there is a strong demand for publicly available post-exposure prophylaxis among high-risk populations in Los Angeles County. view more (2007-11-09)
Fine-tuning lasers to destroy blood-borne diseases like AIDS
Physicists in Arizona State University have designed a revolutionary laser technique which can destroy viruses and bacteria such as AIDS without damaging human cells and may also help reduce the spread of hospital infections such as MRSA. view more (2007-11-01)
AIDS drugs have saved 3 million years of life in the US
Increasingly effective HIV therapy—including a decade of highly active antiretroviral therapy (HAART)—has provided 3 million years of extended life to Americans with AIDS since 1989, report researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). view more (2006-06-05)
|
|
| Page
5 of
17 |
335 Results |
|
|
|
Sort By:
Page Views | Date |
|
